Keros Therapeutics, Inc.
NASDAQ:KROS · NASDAQ Global Market
+$0.13 today
Vol 0.40M · Avg 0.36M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:KROS · Revenue to Net Income
Key Ratios
Analysis
$33.2M of revenue converted into -$85.1M of net income for the selected period. Gross margin is 71.3% and net margin is -3193.4%, showing how much revenue survives after costs and taxes. EPS is $-1.95, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $244.1M +6775.0% | $3.5M +2251.0% | $151.0K | $0 -100.0% | $20.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.5M | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $242.6M +6732.5% | $3.5M +2251.0% | $151.0K | $0 -100.0% | $20.1M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 99.4% -0.6pp | 100.0% +0.0pp | 100.0% | — | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $129.6M -25.3% | $173.6M +28.4% | $135.3M +55.0% | $87.3M +58.3% | $55.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $46.8M +15.0% | $40.8M +17.0% | $34.8M +26.6% | $27.5M +29.0% | $21.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $171.9M -19.8% | $214.4M +26.0% | $170.1M +48.2% | $114.8M +50.1% | $76.5M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.5M +22.8% | $1.2M +50.8% | $815.0K +20.9% | $674.0K +78.3% | $378.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $93.4M +150.3% | -$185.8M -22.1% | -$152.2M -46.3% | -$104.0M -84.6% | -$56.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 38.3% +5272.8pp | -5234.5% +95545.0pp | -100779.5% | — | -280.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $70.6M +133.5% | -$210.8M -24.1% | -$169.9M -48.0% | -$114.8M -103.6% | -$56.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 28.9% +5967.9pp | -5939.0% +106604.8pp | -112543.7% | — | -280.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 -100.0% | $1.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 -100.0% | $1.0K -75.0% | $4.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $21.3M -10.5% | $23.8M +40.3% | $16.9M +67.6% | $10.1M +2908.6% | -$360.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $91.9M +149.1% | -$187.1M -22.3% | -$153.0M -46.2% | -$104.7M -84.5% | -$56.7M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 37.7% +5306.8pp | -5269.1% +96050.1pp | -101319.2% | — | -282.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $4.9M +1527.7% | $300.0K | $0 | $0 -100.0% | $2.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | $87.0M +146.4% | -$187.4M -22.5% | -$153.0M -46.2% | -$104.7M -78.2% | -$58.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | 35.7% +5313.2pp | -5277.5% +96041.7pp | -101319.2% | — | -292.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +146.8% | -$5 +3.8% | -$5 -25.3% | -$4 -64.7% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +146.0% | -$5 +3.8% | -$5 -25.3% | -$4 -64.7% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $37.2M -0.6% | $37.4M +27.1% | $29.4M +16.7% | $25.2M +8.2% | $23.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $37.9M +1.1% | $37.4M +27.1% | $29.4M +16.7% | $25.2M +8.2% | $23.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
Absci Corporation
NASDAQ:ABSI
$1.14B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$995.63M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$804.20M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$609.46M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$472.02M
REGENXBIO Inc.
NASDAQ:RGNX
$419.01M
Verastem, Inc.
NASDAQ:VSTM
$289.73M
Niagen Bioscience Inc
NASDAQ:NAGE
$277.56M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does KROS generate?
Keros Therapeutics, Inc. (KROS) reported $244.06M of revenue in fiscal 2025.
Is KROS profitable?
Keros Therapeutics, Inc. (KROS) reported $87.01M of net income, with a net margin of 35.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.